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BACKGROUND
Patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic 
breast cancer who have disease progression after therapy with multiple HER2-targeted 
agents have limited treatment options. Tucatinib is an investigational, oral, highly 
selective inhibitor of the HER2 tyrosine kinase.
METHODS
We randomly assigned patients with HER2-positive metastatic breast cancer previ-
ously treated with trastuzumab, pertuzumab, and trastuzumab emtansine, who had 
or did not have brain metastases, to receive either tucatinib or placebo, in combina-
tion with trastuzumab and capecitabine. The primary end point was progression-free 
survival among the first 480 patients who underwent randomization. Secondary end 
points, assessed in the total population (612 patients), included overall survival, pro-
gression-free survival among patients with brain metastases, confirmed objective re-
sponse rate, and safety.
RESULTS
Progression-free survival at 1 year was 33.1% in the tucatinib-combination group and 
12.3% in the placebo-combination group (hazard ratio for disease progression or death, 
0.54; 95% confidence interval [CI], 0.42 to 0.71; P<0.001), and the median duration of 
progression-free survival was 7.8 months and 5.6 months, respectively. Overall survival 
at 2 years was 44.9% in the tucatinib-combination group and 26.6% in the placebo-
combination group (hazard ratio for death, 0.66; 95% CI, 0.50 to 0.88; P = 0.005), and 
the median overall survival was 21.9 months and 17.4 months, respectively. Among the 
patients with brain metastases, progression-free survival at 1 year was 24.9% in the 
tucatinib-combination group and 0% in the placebo-combination group (hazard ratio, 
0.48; 95% CI, 0.34 to 0.69; P<0.001), and the median progression-free survival was 7.6 
months and 5.4 months, respectively. Common adverse events in the tucatinib group 
included diarrhea, palmar–plantar erythrodysesthesia syndrome, nausea, fatigue, and 
vomiting. Diarrhea and elevated aminotransferase levels of grade 3 or higher were more 
common in the tucatinib-combination group than in the placebo-combination group.
CONCLUSIONS
In heavily pretreated patients with HER2-positive metastatic breast cancer, including 
those with brain metastases, adding tucatinib to trastuzumab and capecitabine resulted 
in better progression-free survival and overall survival outcomes than adding placebo; 
the risks of diarrhea and elevated aminotransferase levels were higher with tucatinib. 
(Funded by Seattle Genetics; HER2CLIMB ClinicalTrials.gov number, NCT02614794.)
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Approximately 15 to 20% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2).1,2 De-
spite dramatic therapeutic advances over the 
past 20 years, most patients with HER2-positive 
metastatic breast cancer ultimately die from 
their disease.3,4 Moreover, as systemic therapies 
have improved, the incidence of brain metastases, 
for which effective treatment options are limit-
ed, has increased such that brain metastases may 
develop in up to half of patients.5-9 Standard-of-
care treatment for patients with HER2-positive 
metastatic breast cancer is first-line trastuzumab 
plus pertuzumab and a taxane, followed by 
second-line trastuzumab emtansine for patients 
who have disease progression.10-12 After progres-
sion during treatment with trastuzumab emtan-
sine, no single regimen is considered the stan-
dard of care; commonly used regimens include 
tyrosine kinase inhibitors such as lapatinib with 
trastuzumab or capecitabine, trastuzumab with 
chemotherapy, or participation in a clinical trial.
Treatment for brain metastases in patients 
with HER2-positive breast cancer includes local 
therapies, such as neurosurgical resection and 
stereotactic (or whole-brain) radiation therapy.13 
Although limited antitumor activity in the brain 
has been reported for some systemic HER2-tar-
geted agents, including tyrosine kinase inhibi-
tors and chemotherapy,14-18 data from random-
ized trials showing better treatment outcomes in 
these patients are lacking.
Tucatinib is an investigational, oral tyrosine 
kinase inhibitor that is highly selective for the 
kinase domain of HER2 with minimal inhibition 
of epidermal growth factor receptor, which may 
alter the toxicity profile.19,20 In a phase 1b dose-
escalation trial, tucatinib in combination with 
trastuzumab and capecitabine showed encourag-
ing antitumor activity in patients with HER2-
positive metastatic breast cancer, including those 
with brain metastases. This regimen was also 
associated with diarrhea, nausea, palmar–plantar 
erythrodysesthesia syndrome, fatigue, and vom-
iting; however, each grade 3 or higher treatment-
related toxic effect (fatigue, diarrhea, and palmar-
plantar erythrodysesthesia syndrome) occurred in 
no more than 10% of patients.21 The HER2CLIMB 
trial evaluated tucatinib combined with trastuzu-
mab and capecitabine in patients with HER2-
positive metastatic breast cancer previously treated 
with trastuzumab, pertuzumab, and trastuzumab 
emtansine.
Me thods
Trial Design and Oversight
We conducted an international, randomized, 
double-blind trial in which the combination of 
tucatinib plus trastuzumab and capecitabine was 
compared with placebo plus trastuzumab and 
capecitabine. The trial was conducted in accor-
dance with regulatory requirements and Interna-
tional Conference on Harmonisation Good Clin-
ical Practice guidelines. The protocol, available 
with the full text of this article at NEJM.org, was 
approved by institutional review boards and eth-
ics committees, according to the practice at each 
participating trial site. All patients provided 
written informed consent. A steering committee 
provided scientific advice, and an independent 
data and safety monitoring committee oversaw 
the conduct of the trial. The steering committee 
and representatives of the sponsor (Seattle Ge-
netics) designed the trial. The authors wrote the 
manuscript with the assistance of a medical 
writer funded by the sponsor. All the authors 
had full access to the relevant data, vouch for the 
completeness and accuracy of the data and for 
adherence of the trial to the protocol, and had 
final responsibility for the content of the man-
uscript and for the decision to submit the manu-
script for publication.
Patients
Patients 18 years of age or older were eligible to 
participate if they had advanced breast carcinoma 
that had been determined to be HER2-positive 
on the basis of immunohistochemical analysis, 
in situ hybridization, or fluorescence in situ hy-
bridization and confirmed at a central location; 
had previously been treated with trastuzumab, 
pertuzumab, and trastuzumab emtansine; and 
had an Eastern Cooperative Oncology Group 
(ECOG) performance-status score of 0 or 1 (on a 
5-point scale in which higher numbers reflect 
greater disability). Patients were excluded if they 
had previously received treatment for metastatic 
disease with capecitabine or a HER2-targeted 
tyrosine kinase inhibitor (although patients who 
had received lapatinib more than 12 months 
before initiating a trial regimen were eligible for 
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inclusion). Patients with brain metastases were 
included unless they were in need of immediate 
local intervention, in which case they could re-
ceive local therapy and be enrolled subsequently. 
Patients with untreated brain metastases larger 
than 2 cm in diameter could be enrolled with 
approval from the medical monitor. Patients with 
leptomeningeal disease were excluded. A com-
plete list of eligibility criteria is provided in the 
protocol.
Randomization and Treatment
Patients were randomly assigned in a 2:1 ratio to 
receive either tucatinib (300 mg orally twice 
daily throughout the treatment period) or pla-
cebo (orally twice daily), in combination with 
trastuzumab (6 mg per kilogram of body weight 
intravenously once every 21 days, with an initial 
loading dose of 8 mg per kilogram; subcutane-
ous administration was allowed) and capecitabine 
(1000 mg per square meter of body-surface area 
orally twice daily on days 1 to 14 of each 21-day 
cycle) (Fig. S1 in the Supplementary Appendix, 
available at NEJM.org). Patients were stratified 
according to whether brain metastases were 
present (yes or no), ECOG performance-status 
score (0 or 1), and geographic region (United 
States, Canada, or the rest of the world).
Assessments
Contrast-enhanced spiral computed tomography 
(CT), positron-emission tomography–CT, or con-
trast-enhanced magnetic resonance imaging 
(MRI) (or combinations thereof) was performed 
at baseline, every 6 weeks for 24 weeks, and every 
9 weeks thereafter. MRI of the head at baseline 
was required for all patients; those with brain 
metastases on the baseline scan underwent a 
contrast MRI of the head at the same intervals. 
Disease response and progression were evaluated 
in accordance with Response Evaluation Criteria 
in Solid Tumors (RECIST) criteria, version 1.1,22 
by means of blinded independent central review. 
Laboratory assessments were performed at least 
every 3 weeks throughout the treatment period 
and 30 days after the last trial treatment date.
Safety was assessed on the basis of the inci-
dence of adverse events (defined according to 
the Medical Dictionary for Regulatory Activities, ver-
sion 22.0, and the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events, 
version 4.03). Changes in vital signs and labora-
tory results were assessed in patients who received 
at least one dose of any trial drug or placebo.
End Points
The primary end point was progression-free sur-
vival (defined as the time from randomization to 
documented disease progression, as assessed 
by means of blinded independent central review, or 
death from any cause, whichever occurred first) 
in the first 480 patients who underwent ran-
domization (primary end-point analysis popula-
tion). Multiplicity-adjusted secondary end points 
were assessed in the total population and in-
cluded overall survival (defined as the time from 
randomization to death from any cause); pro-
gression-free survival, as assessed by means of 
blinded independent central review, among the 
patients who had brain metastases at baseline; 
and confirmed objective response rate (defined 
as the percentage of patients with measurable 
disease at baseline who had a confirmed com-
plete response or partial response, as assessed by 
means of blinded independent central review). 
Safety was a secondary end point.
Statistical Analysis
The primary end-point analysis was to be per-
formed after approximately 288 events had oc-
curred in the primary end-point analysis popula-
tion, which would provide 90% power to detect 
a hazard ratio of 0.67 with a two-sided log-rank 
test at an alpha level of 0.05. If the result with 
respect to the primary end point was significant, 
overall survival and progression-free survival 
among the patients with brain metastases were 
to be tested in parallel at alpha levels of 0.02 and 
0.03, respectively, in the first interim analysis. 
The final analyses for these two variables were 
to be performed with 361 and 220 events, re-
spectively. Approximately 600 patients were to 
undergo randomization in order for the required 
number of events to be accumulated (see the 
Statistical Methods section in the Supplementa-
ry Appendix). Overall type I error in the interim 
and final analyses of overall survival in the total 
population and progression-free survival among 
the patients with brain metastases was con-
trolled with the use of the group sequential 
Holm variable procedure23 with the Lan–DeMets 
alpha-spending function with an O’Brien–Fleming 
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boundary. If the results with respect to both 
overall survival in the total population and pro-
gression-free survival among the patients with 
brain metastases were significant, the between-
group difference in the percentage of patients 
who had a confirmed objective response was to 
be tested at a two-sided alpha level of 0.05.
The size of the initial trial population (180 
patients) was increased to 480 to provide ade-
quate statistical power to evaluate the end point 
of progression-free survival and increase the 
power of the subgroup analyses. The size of the 
trial population was later increased to approxi-
mately 600 patients to ensure sufficient power to 
show a progression-free survival benefit among 
the patients with brain metastases. At no point 
were these decisions based on an assessment 
of the ongoing results, and blinding was never 
broken.
The Kaplan–Meier method was used to esti-
mate progression-free survival and overall survival 
time curves, median progression-free survival and 
overall survival, and 95% confidence intervals for 
the treatment groups. Cox proportional-hazards 
models, with stratification factors taken into ac-
count, were used to estimate hazard ratios and 
95% confidence intervals. The treatment groups 
were compared with the use of a stratified log-
rank test, and P values were calculated by means 
of a rerandomization procedure to reflect the 
dynamic, hierarchical randomization scheme.24 
In the analysis of progression-free survival, data 
from patients without any documented event or 
who received anticancer therapy not specified in 
the protocol were censored at the date the pa-
tient was last known to be event-free. The cen-
soring scheme for the primary end point is de-
scribed in the statistical analysis plan (available 
with the protocol at NEJM.org). The P value for 
the between-group comparison of the percent-
age of patients who had a confirmed objective 
response was calculated with the use of a strati-
fied Cochran–Mantel–Haenszel test.
At the date of data cutoff (September 4, 2019), 
a total of 275 events of disease progression or 
death had occurred in the primary end-point 
analysis population, 215 deaths had occurred in 
the total population, and 157 events of disease 
progression or death had occurred among the 
patients with brain metastases in the total popu-
lation. On the basis of the observed number of 
events, the multiplicity-adjusted, two-sided alpha 
levels at the first interim analysis were 0.007 for 
overall survival and 0.008 for progression-free 
survival among the patients with brain metastases.
R esult s
Patient Characteristics
Between February 23, 2016, and May 3, 2019, a 
total of 612 patients were enrolled at 155 sites in 
15 countries (total population); 410 were ran-
domly assigned to the tucatinib-combination 
group and 202 to the placebo-combination group. 
In the primary end-point analysis population 
(480 patients), 320 patients were randomly as-
signed to the tucatinib-combination group and 
160 to the placebo-combination group (Fig. S1 in 
the Supplementary Appendix). The median dura-
tion of follow-up in the total population was 
14.0 months. Patient demographic and disease 
characteristics at baseline were well balanced 
between the treatment groups (Table 1). In the 
total population, 291 patients (47.5%) had brain 
metastases at baseline — 48.3% in the tucatinib-
combination group and 46.0% in the placebo-
combination group (Table S1).
Efficacy in the Primary End-Point Population
At 1 year, the estimated progression-free sur-
vival was 33.1% (95% confidence interval [CI], 
26.6 to 39.7) in the tucatinib-combination group 
and 12.3% (95% CI, 6.0 to 20.9) in the placebo-
combination group, and the median duration 
of progression-free survival was 7.8 months 
(95% CI, 7.5 to 9.6) and 5.6 months (95% CI, 4.2 
to 7.1), respectively. The risk of disease progres-
sion or death, as assessed by means of blinded 
independent central review in the primary end-
point analysis population, was 46% lower in the 
tucatinib-combination group than in the place-
bo-combination group (hazard ratio, 0.54; 95% 
CI, 0.42 to 0.71; P<0.001) (Fig. 1A). Hazard ra-
tios across all subgroups were consistent with 
the hazard ratio in the overall analysis (Fig. 1B). 
A comparison of investigator-assessed progres-
sion-free survival between the treatment groups 
yielded results consistent with those in the 
primary end-point analysis (Fig. S2).
Efficacy in the Total Trial Population
At 2 years, the estimated overall survival was 
44.9% (95% CI, 36.6 to 52.8) in the tucatinib-
combination group and 26.6% (95% CI, 15.7 to 
38.7) in the placebo-combination group, and the 
median duration of overall survival was 21.9 
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Characteristic
















Female sex — no. (%) 317 (99.1) 158 (98.8) 407 (99.3) 200 (99.0)
Age — no. (%)
<65 yr 252 (78.8) 132 (82.5) 328 (80.0) 168 (83.2)
≥65 yr 68 (21.2) 28 (17.5) 82 (20.0) 34 (16.8)
Median age — yr 54.0 54.0 55.0 54.0
Race — no. (%)†
Asian 17 (5.3) 3 (1.9) 18 (4.4) 5 (2.5)
Black 30 (9.4) 13 (8.1) 41 (10.0) 14 (6.9)
White 225 (70.3) 125 (78.1) 287 (70.0) 157 (77.7)
Unknown or other 48 (15.0) 19 (11.9) 64 (15.6) 26 (12.9)
Geographic region — no. (%)
United States and Canada 204 (63.8) 103 (64.4) 246 (60.0) 123 (60.9)
Rest of the world 116 (36.2) 57 (35.6) 164 (40.0) 79 (39.1)
Hormone‑receptor status — no. (%)
Positive for ER or PR or both 190 (59.4) 99 (61.9) 243 (59.3) 127 (62.9)
Negative for ER and PR 126 (39.4) 61 (38.1) 161 (39.3) 75 (37.1)
Other 4 (1.2) 0 6 (1.5) 0
ECOG performance‑status score — no. (%)‡
0 159 (49.7) 76 (47.5) 204 (49.8) 94 (46.5)
1 161 (50.3) 84 (52.5) 206 (50.2) 108 (53.5)
Stage IV at initial diagnosis — no. (%) 108 (33.8) 67 (41.9) 143 (34.9) 77 (38.1)
Presence or history of brain metastases — no. (%) 148 (46.2) 71 (44.4) 198 (48.3) 93 (46.0)
Location of other metastases — no. (%)
Lung 160 (50.0) 82 (51.2) 200 (48.8) 100 (49.5)
Liver 108 (33.8) 64 (40.0) 137 (33.4) 78 (38.6)
Bone 178 (55.6) 85 (53.1) 223 (54.4) 111 (55.0)
Previous lines of therapy, median no. (range) 4 (2–14) 4 (2–17) 4 (2–14) 4 (2–17)
Previous lines of therapy for metastatic cancer, median 
no. (range)
3 (1–14) 3 (1–13) 3 (1–14) 3 (1–13)
Previous therapies — no. (%)
Trastuzumab 320 (100) 160 (100) 410 (100) 202 (100)
Pertuzumab 320 (100) 159 (99.4) 409 (99.8) 201 (99.5)
Trastuzumab emtansine 320 (100) 160 (100) 410 (100) 202 (100)
Lapatinib 22 (6.9) 10 (6.2) 24 (5.9) 10 (5.0)
*  The primary end‑point analysis population included the first 480 patients who were randomly assigned to the tucatinib‑combination group 
(tucatinib plus trastuzumab and capecitabine) or to the placebo‑combination group (placebo plus trastuzumab and capecitabine), and the 
total population included 612 patients who underwent randomization. Randomization stratification factors included geographic region 
(United States, Canada, or the rest of the world), presence or history of brain metastases (yes or no), and Eastern Cooperative Oncology 
Group (ECOG) performance‑status score (0 or 1). ER denotes estrogen receptor, and PR progesterone receptor. Data from the patients in 
the United States and Canada were combined for this analysis.
†  Race was determined by the local investigator.
‡  ECOG performance‑status scores range from 0 to 5, with higher scores indicating greater disability.
Table 1. Patient Demographic and Disease Characteristics in the Primary End-Point Analysis Population and the Total Population.*
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Figure 1. Kaplan–Meier Estimates of Progression-free Survival in the Primary End-Point Analysis Population 
and Prespecified Subgroups.
Panel A shows the Kaplan–Meier estimates of progression‑free survival in the primary end‑point analysis population, 
which included the first 480 patients who underwent randomization. Progression‑free survival was assessed by 
means of blinded independent central review. The number of events is the number of events of disease progression 
or death. The dashed vertical lines indicate landmark time points. Panel B shows the analysis of progression‑free 
survival in prespecified subgroups. Scores for the Eastern Cooperative Oncology Group (ECOG) performance status 
range from 0 to 5, with higher scores indicating greater disability. Data from the patients in the United States and 
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months (95% CI, 18.3 to 31.0) and 17.4 months 
(95% CI, 13.6 to 19.9), respectively. In the total 
population, the risk of death was 34% lower in 
the tucatinib-combination group than in the 
placebo-combination group (hazard ratio, 0.66; 
95% CI, 0.50 to 0.88; P = 0.005) (Fig. 2A). Hazard 
ratios across all subgroups were consistent with 
the hazard ratio in the overall analysis (Fig. 2B). 
In addition, progression-free survival in the total 
population was consistent with that in the pri-
mary end-point analysis (Fig. S3).
Among the patients with brain metastases, 
Figure 2. Kaplan–Meier Estimates of Overall Survival in the Total Population and Prespecified Subgroups.
Panel A shows the Kaplan–Meier estimates of overall survival in the total population, which included 612 patients 
who underwent randomization. The dashed vertical lines indicate landmark time points. Panel B shows the analysis 
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the estimated progression-free survival at 1 year 
was 24.9% (95% CI, 16.5 to 34.3) in the tuca-
tinib-combination group and 0% in the placebo-
combination group, and the median duration of 
progression-free survival was 7.6 months (95% 
CI, 6.2 to 9.5) and 5.4 months (95% CI, 4.1 to 
5.7), respectively. The risk of disease progression 
or death was 52% lower in the tucatinib-combi-
nation group than in the placebo-combination 
group (hazard ratio, 0.48; 95% CI, 0.34 to 0.69; 
P<0.001) (Fig. 3A). Hazard ratios across all sub-
groups were consistent with the hazard ratio in 
the overall analysis (Fig. 3B). In a prespecified 
analysis involving the patients without brain 
metastases, the risk of disease progression or 
death was 43% lower in the tucatinib-combina-
tion group than in the placebo-combination group 
(hazard ratio, 0.57; 95% CI, 0.41 to 0.80) (Fig. S4). 
Among the 511 patients with measurable disease 
at baseline, as assessed by means of blinded in-
dependent central review, the percentage who 
had a confirmed objective response was 40.6% 
(95% CI, 35.3 to 46.0) in the tucatinib-combina-
tion group and 22.8% (95% CI, 16.7 to 29.8) in the 
placebo-combination group (P<0.001) (Table S2).
Treatment Duration
In the primary end-point analysis population, the 
median duration of exposure to tucatinib was 
7.3 months (range, <0.1 to 35.1), and the median 
duration of exposure to placebo was 4.4 months 
(range, <0.1 to 24.0); the durations of exposure 
to trastuzumab and capecitabine were also short-
er in the placebo-combination group. Among 
the 601 patients who received at least one dose 
of any trial drug or placebo, the median duration 
of exposure to tucatinib or placebo was 5.8 
months (range, <0.1 to 35.1) and 4.4 months 
(range, <0.1 to 24.0), respectively. At the date of 
data cutoff, 118 of 410 patients (28.8%) in the 
tucatinib-combination group and 27 of 202 
(13.4%) in the placebo-combination group were 
continuing to receive their assigned treatment.
Safety
The occurrence of adverse events according to 
treatment group is summarized in Table 2 and 
Table S3. Adverse events led to the discontinua-
tion of tucatinib in 5.7% of the patients, to the 
discontinuation of placebo in 3.0% of the pa-
tients (Table S4), and to the discontinuation of 
capecitabine in 9.8% of the patients (10.1% in 
the tucatinib-combination group and 9.1% in the 
placebo-combination group).
The most common adverse events observed 
among the patients in the tucatinib-combination 
group were diarrhea, palmar–plantar erythro-
dysesthesia syndrome, nausea, fatigue, and vom-
iting (Table 2); most events were of grade 1 or 2. 
The most common adverse events of grade 3 or 
higher observed among the patients in the tuca-
tinib-combination group were palmar–plantar 
erythrodysesthesia syndrome, diarrhea, elevations 
in alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) levels, and fatigue.
Diarrhea was the most common adverse event 
in both the tucatinib-combination group and the 
placebo-combination group, and most events of 
diarrhea were of grade 1 (in 43.3% and 32.0% of 
the patients, respectively) or grade 2 (in 24.8% 
and 12.7%, respectively); diarrhea of grade 3 or 
higher occurred in 12.9% and 8.6%, respectively. 
Antidiarrheal prophylaxis was not mandated. 
Among the patients who used antidiarrheal 
agents, the median duration of use was 3 days 
per cycle in both treatment groups.
Elevations in the ALT and AST levels were 
mostly low-grade, transient, and reversible; ALT 
and AST elevations that were of grade 3 or 
higher occurred in 5.4% and 4.5% of the pa-
tients, respectively, in the tucatinib-combination 
group and in 0.5% of the patients (for each) in 
the placebo-combination group. Elevations in the 
bilirubin level of any grade occurred in 18.6% of 
the patients in the tucatinib-combination group 
and in 10.2% of those in the placebo-combina-
tion group; however, elevations of grade 3 or 
higher occurred in fewer patients in the tuca-
tinib-combination group (0.7% vs. 2.5%).
Increases in the serum creatinine level were 
observed in 13.9% of the patients in the tuca-
tinib-combination group and in 1.5% of those in 
the placebo-combination group. Tucatinib has been 
shown to inhibit the multidrug and toxin extru-
sion protein 1 and 2-K (MATE1 and MATE2-K) 
transporters, which increases the serum creati-
nine level without affecting glomerular function 
(see the Supplementary Appendix). Increases in 
the serum creatinine level occurred early, re-
mained clinically nonsignificant during the 
treatment period with no intervention to lower 
the level, were reversible, and were not the cause 
of discontinuation of therapy in any patient.
Of 215 deaths that occurred during the trial, 
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the most common cause in both treatment 
groups was disease progression. Adverse events 
were the cause of death in 6 of 404 patients 
(1.5%) in the tucatinib-combination group (car-
diac arrest, cardiac failure, dehydration, multiple-
organ dysfunction syndrome, sepsis, and septic 
shock in 1 patient each) and in 5 of 197 patients 
(2.5%) in the placebo-combination group (cardiac 
arrest, multiple-organ dysfunction syndrome, 
myocardial infarction, sepsis, and systemic in-
flammatory response syndrome in 1 patient each).
 Discussion
Among patients with HER2-positive metastatic 
breast cancer previously treated with trastuzu-
Figure 3. Kaplan–Meier Estimates of Progression-free Survival among the Patients with Brain Metastases in the Total 
Population and Prespecified Subgroups.
Panel A shows the Kaplan–Meier estimates of progression‑free survival among 291 patients with brain metastases 
in the total population, as assessed by means of blinded independent central review. The number of events is the 
number of events of disease progression or death. Panel B shows the analysis of progression‑free survival in pre‑
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mab, pertuzumab, and trastuzumab emtansine, 
the addition of tucatinib to trastuzumab and 
capecitabine resulted in a clinically meaningful 
lower risk of disease progression or death than 
the addition of placebo. Most importantly, over-
all survival was longer by 4.5 months with tuca-
tinib (median of 21.9 months vs. 17.4 months).
The tucatinib combination was associated 
with a significantly lower risk of disease pro-
gression or death than the placebo combination 
among patients with metastatic HER2-positive 
breast cancer with brain metastases. Previous 
studies have shown that the combination of a 
HER2 tyrosine kinase inhibitor with capecitabine 
has some activity in brain metastases from 
HER2-positive breast cancer.17,25 However, toxic 
effects, including those associated with inhibi-
tion of epidermal growth factor receptor, have 
limited the use of these combinations.
The survival benefit with tucatinib was ob-
served in the total HER2CLIMB trial population 
and across all subgroups tested. In addition, the 
results showed that, in combination with 
capecitabine, simultaneous targeting of the in-
ternal domain of HER2, as well as the external 
domain with trastuzumab, led to substantially 
better survival outcomes than did targeting the 
external domain alone.
Patients were enrolled across 155 sites in 15 
countries, and all patients had received previous 
treatment with the current standard of care 
(trastuzumab, pertuzumab, and trastuzumab 
emtansine). The comparator group received a 
recommended regimen for management in this 
clinical context, as supported by a randomized, 
phase 3 trial that showed longer progression-
free and overall survival among patients treated 
with trastuzumab plus capecitabine than among 
those treated with lapatinib plus capecitabine.26 
Survival outcomes in the placebo-combination 
group in our trial were similar to those in other 
contemporary trials of HER2-targeted therapy.25,27
In our trial, we enrolled a large percentage of 
patients with untreated or previously treated 
progressing brain metastases, a population typi-
cally excluded from clinical trials despite this 
condition being a common clinical problem. The 
inclusion of patients with brain metastases in 
the initial phase 1 trials of tucatinib generated 






Any Grade Grade ≥3 Any Grade Grade ≥3
number of patients (percent)
Any adverse event 401 (99.3) 223 (55.2) 191 (97.0) 96 (48.7)
Diarrhea 327 (80.9) 52 (12.9) 105 (53.3) 17 (8.6)
PPE syndrome 256 (63.4) 53 (13.1) 104 (52.8) 18 (9.1)
Nausea 236 (58.4) 15 (3.7) 86 (43.7) 6 (3.0)
Fatigue 182 (45.0) 19 (4.7) 85 (43.1) 8 (4.1)
Vomiting 145 (35.9) 12 (3.0) 50 (25.4) 7 (3.6)
Stomatitis 103 (25.5) 10 (2.5) 28 (14.2) 1 (0.5)
Decreased appetite 100 (24.8) 2 (0.5) 39 (19.8) 0
Headache 87 (21.5) 2 (0.5) 40 (20.3) 3 (1.5)
Aspartate aminotransferase in‑
creased
86 (21.3) 18 (4.5) 22 (11.2) 1 (0.5)
Alanine aminotransferase in‑
creased
81 (20.0) 22 (5.4) 13 (6.6) 1 (0.5)
*  Listed are adverse events that were reported in at least 20% of the patients in the tucatinib‑combination group. Safety 
analyses included all the patients who received at least one dose of any trial drug or placebo. Data are reported accord‑
ing to preferred terms in the Medical Dictionary for Regulatory Activities, version 22.0. PPE denotes palmar–plantar eryth‑
rodysesthesia.
Table 2. Most Common Adverse Events.*
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sion in HER2CLIMB and is in line with current 
recommendations from the American Society of 
Clinical Oncology–Friends of Cancer Research 
Eligibility Criteria Working Group.28
Tucatinib in combination with trastuzumab 
and capecitabine was associated with toxic ef-
fects, with the majority of adverse events being 
low grade. Safety events of note included diar-
rhea that was managed with short courses of 
antidiarrheal agents and transient, reversible ele-
vations in liver enzyme levels. A majority of pa-
tients in the tucatinib-combination group had 
toxic effects, but less than 6% of the patients 
discontinued treatment with tucatinib as a con-
sequence.
In conclusion, tucatinib plus trastuzumab and 
capecitabine is an active combination in heavily 
pretreated patients with HER2-positive meta-
static breast cancer, including those with previ-
ously untreated, treated and stable, or treated 
and progressing brain metastases.
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